A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
about
Accounting for the relationship between per diem cost and LOS when estimating hospitalization costsPharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey.Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literatureCost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses.Economic evaluation of voriconazole for the treatment of candidemia in Canadian adults.Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting.Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.Caspofungin: when and how? The microbiologist's view.Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.Pharmacoeconomic assessment of therapy for invasive aspergillosis.Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients.Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.Echinocandins in antifungal pharmacotherapy.Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden.Echinocandins: A ray of hope in antifungal drug therapyBiomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals.Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.Should cost considerations be included in medical decisions? No.Economic evaluation of micafungin vs. Liposomal Amphotericin B (LAmB) for the treatment of candidaemia and Invasive Candidiasis (IC)Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis
P2860
Q34496753-726E909F-871F-4857-95AD-38713CDBD7EDQ35054434-B32F0E32-C6A8-48A1-AC9E-144D4414445BQ35168703-AB7FFBD8-BEE2-499F-9F36-D0398C3B8EF5Q35959484-565C43F7-CE84-4DDF-A92B-EAFA7AD972C2Q36056617-08847D43-7B77-4C51-A3D8-4B4055FB5E2FQ37021364-18407312-A97E-44AE-9430-1FC8B36DA61FQ37157379-7EEE972E-4954-4EEB-8E77-6CEE7E8F46B5Q37480190-46C95F9F-DC81-4A59-A2A5-05624B599E76Q37864429-0DE92424-F5C9-4DD7-BBD0-886FDC3E35C7Q37888750-781C8B67-7E1B-4AEC-B777-E998113ECD6AQ37925817-57A249B2-1253-4C21-908E-56C481BB2400Q38073334-9333FA7D-8A18-4C4F-AC62-4317F3184EECQ38097528-EA071C73-B9D1-453B-B7AE-0C914FA16D0AQ38682970-B301CB0C-48A3-4F2C-9836-3D62119E3362Q39458862-062E43F8-ECB3-4F58-B405-9499CAD4E3F0Q40333474-4D087305-8329-4247-811E-D71093DB996DQ41066834-84F7B296-9E4C-49DF-BDED-B71AC47001CDQ41703512-492B99A9-20C1-4947-BB5D-8BFF4250A775Q44612152-3CFC7701-A5CF-4FB7-A107-58FCED562904Q46089515-726402C9-ACDA-4993-934A-D4ED5276C02BQ48001809-D7EB4FAB-01DA-4AA7-91B5-C4075DEA373FQ57746129-BEC7CF96-0E5E-495F-8CCB-9AD6AB32204BQ57746135-07045AC8-040C-4097-8D68-24E30E2665D1
P2860
A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A cost-effectiveness analysis ...... d fungal infections in the UK.
@ast
A cost-effectiveness analysis ...... d fungal infections in the UK.
@en
type
label
A cost-effectiveness analysis ...... d fungal infections in the UK.
@ast
A cost-effectiveness analysis ...... d fungal infections in the UK.
@en
prefLabel
A cost-effectiveness analysis ...... d fungal infections in the UK.
@ast
A cost-effectiveness analysis ...... d fungal infections in the UK.
@en
P2093
P2860
P1476
A cost-effectiveness analysis ...... d fungal infections in the UK.
@en
P2093
Catherine McKenzie
Chris Poynton
Jeroen P Jansen
Karin Bruynesteyn
Ritesh N Kumar
Tony Pagliuca
Vanya Gant
P2860
P304
P356
10.1111/J.1600-0609.2007.00850.X
P577
2007-04-05T00:00:00Z